Bristol-Myers Squibb Co
XMUN:BRM
Bristol-Myers Squibb Co
XMUN:BRM
Price:
51.59
EUR
-0.33%
Market Closed
Market Cap:
€105B
Relative Value
The Relative Value of one
BRM
stock under the Base Case scenario is
59.3
EUR.
Compared to the current market price of 51.59 EUR,
Bristol-Myers Squibb Co
is
Undervalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BRM
Relative Value
Base Case
59.3
EUR
Undervaluation 13%
Multiples Across Competitors
BRM Competitors Multiples
Bristol-Myers Squibb Co Competitors
Bristol-Myers Squibb Co Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
XMUN:BRM
|
115.7B EUR | 2.4 | 16.4 | 7 | 8.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 4.9 | 28.3 | 15.7 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| FR |
|
Sanofi SA
PAR:SAN
|
93.7B EUR | 2 | 12 | 10.1 | 10.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
